Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2009
- First approval year
- 2009
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid
- streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid component of synflorix
- Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid component of synflorix
- streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid
- Streptococcus pneumoniae polysaccharide conjugated to corynebacterium diphtheriae toxoid
- ChEMBL ID
- CHEMBL6068365
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Polysaccharide conjugated to Corynebacterium diphtheriae toxoid vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Polysaccharide conjugated to Corynebacterium diphtheriae toxoid
- Condition
- Pneumococcal Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000772
- Subject identifier
- D011008
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition identifier
- EFO_1001476
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005114
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (24)
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
- A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
- A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia
- A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
- An Alternative Booster Vaccine Against Meningitis and Ear Infections
- Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
- Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
- Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine
- Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants
- Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV)
- PCV10 Immunogenicity Study Nepal 2015
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
- Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above
- Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
- Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
- Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines
- Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
- Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule
- Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants
Approved for (1)
In development for (1)
- Streptococcal infection Phase 3